| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
We identified two promising factors, Lysophosphatidic acid receptor 2 (LPA) and Na+/H+ exchange regulatory factor 2 (NHERF2) which have some funcions to regulate AR and induce chemoresistance. However, the analysis with clinical samples showed that AR expression did not contribute poor prognosis and the additional laboratory investigation was not able to detect AR nuclear translocation in pancreatic cancer cell lines, which required the revision of our initial study design. We focused on LPA2 and NHERF2 as the oncogenic and chemoresistant factor in colon cancer, instead of pancreatic cancer. We kept experiments and got data which showed LPA2 and NHERF2 had specific functions in terms of carciogenesis and chemoresistance. In addition, we performed SNPs and IHC analysis in pancreatic cancer patients and found p53 and MDM2 as specific biomarkers.
|
